Risk management experience for innovative drugs of FDA and MHRA derived from the marketing or withdrawal of natalizumab
Journal Articles
- Overview
- Additional Document Info
- View All
Overview
status
publication date
- October 14, 2010
has subject area
- General & Internal Medicine (Science Metrix)